Generic Ionsys Availability
Last updated on Apr 10, 2025.
Ionsys is a brand name of fentanyl, approved by the FDA in the following formulation(s):
IONSYS (fentanyl hydrochloride - system;iontophoresis, transdermal)
-
Manufacturer: THE MEDICINES CO
Approval date: May 22, 2006
Strength(s): EQ 40MCG BASE/ACTIVATION (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ionsys. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Two-part electrotransport device
Patent 8,301,238
Issued: October 30, 2012
Inventor(s): Netzel; Zita S. et al.
Assignee(s): Incline Therapeutics, Inc. (Redwood City, CA); Alza Corporation (Vacaville, CA)A switch operated therapeutic agent delivery device is described. The device comprises two parts, which are assembled by a user prior to use. A first part contains a power supply and circuitry for the device; and a second part comprises electrodes and reservoirs containing the therapeutic agent to be delivered. The action of combining the two parts of the device causes the two parts to be irreversibly coupled together, completes an electrical connection between the two parts, and closes one or more switches, thereby connecting a power source, such as a battery, into the device's circuitry, thereby powering the device on so that it is ready for use. The device can then be attached to a patient, who can operate the device by pressing a button in a proper sequence.
Patent expiration dates:
- September 30, 2031✓
- September 30, 2031
-
Self-test for analgesic product
Patent 8,428,708
Issued: April 23, 2013
Inventor(s): White; Bradley E. et al.
Assignee(s): Incline Therapeutics, Inc. (Redwood City, CA); Alza Corporation (Vacaville, CA)Electrotransport drug delivery devices, system and methods of using configured to determine if a current is present between the anode and cathode when drug is not intended to be delivered by the device. These devices/systems may include an off-current module to determine that any current (e.g., which may be inferred by measuring potential difference between the anode and cathode of the device) flowing between the anode and cathode is below a threshold value when the device is not supposed to be delivering drug, thereby preventing unintended delivery of drug and/or alerting a user that unintended delivery of drug may occur.
Patent expiration dates:
- May 21, 2032✓
- May 21, 2032
-
Current control for electrotransport drug delivery
Patent 8,428,709
Issued: April 23, 2013
Inventor(s): White; Bradley E. et al.
Assignee(s): Incline Therapeutics, Inc. (Redwood City, CA); Alza Corporation (Vacaville, CA)Devices, systems and methods for controlling the application of current and/or voltage to deliver drug from patient contacts of an electrotransport drug delivery device by indirectly controlling and/or monitoring the applied current without directly measuring from the cathode of the patient terminal. In particular, described herein are electrotransport drug delivery systems including constant current delivery systems having a feedback current and/or voltage control module that is isolated from the patient contacts (e.g., anodes and cathodes). The feedback module may be isolated by a transistor from the patient contacts; feedback current and/or voltage control measurements may be performed at the transistor rather than at the patient contact (e.g., cathode).
Patent expiration dates:
- June 11, 2032✓✓
- June 11, 2032
-
Switch validation circuit and method
Patent 8,781,571
Issued: July 15, 2014
Inventor(s): Lemke John & Satre Scot & Chen Corinna X. & Read Brian W.
Assignee(s): Incline Therapeutics, Inc.A switch operated therapeutic agent delivery device is described. Embodiments of the operated therapeutic agent delivery device include a switch that can be operated by a user, a device controller connected to the switch through a switch input where the device can actuate the device when certain predetermined conditions are met, and a switch integrity subcircuit which is used to detect a fault or a precursor to a fault.
Patent expiration dates:
- March 31, 2032✓✓
- March 31, 2032
-
Self-test for analgesic product
Patent 9,095,706
Issued: August 4, 2015
Inventor(s): White; Bradley E. et al.
Assignee(s): Incline Therapeutics, Inc. (Redwood City, CA); Alza Corporation (Vacaville, CA)Electrotransport drug delivery devices, system and methods of using configured to determine if a current is present between the anode and cathode when drug is not intended to be delivered by the device. These devices/systems may include an off-current module to determine that any current (e.g., which may be inferred by measuring potential difference between the anode and cathode of the device) flowing between the anode and cathode is below a threshold value when the device is not supposed to be delivering drug, thereby preventing unintended delivery of drug and/or alerting a user that unintended delivery of drug may occur.
Patent expiration dates:
- February 3, 2033✓
- February 3, 2033
-
Method of storing an electrotransport drug delivery device
Patent 9,364,656
Issued: June 14, 2016
Inventor(s): Netzel; Zita S. et al.
Assignee(s): Incline Therapeutics, Inc. (Redwood City, CA); Alza Corporation (Vacaville, CA)A switch operated therapeutic agent delivery device is described. The device comprises two parts, which are assembled by a user prior to use. A first part contains a power supply and circuitry for the device; and a second part comprises electrodes and reservoirs containing the therapeutic agent to be delivered. The action of combining the two parts of the device causes the two parts to be irreversibly coupled together, completes an electrical connection between the two parts, and closes one or more switches, thereby connecting a power source, such as a battery, into the device's circuitry, thereby powering the device on so that it is ready for use. The device can then be attached to a patient, who can operate the device by pressing a button in a proper sequence.
Patent expiration dates:
- September 30, 2031✓
- September 30, 2031
-
Switch validation circuit and method
Patent 9,731,121
Issued: August 15, 2017
Inventor(s): Lemke John & Satre Scot & Chen Corinna X. & Read Brian W. & Dougherty Jason E. & Joshi Nitin B.
Assignee(s): Incline Therapeutics, Inc.A switch-operated therapeutic agent delivery device is described. Embodiments of the operated therapeutic agent delivery device include a switch that can be operated by a user, a device controller connected to the switch through a switch input where the device can actuate the device when certain predetermined conditions are met, following performance of both a digital switch validation test and an analog switch validation test.
Patent expiration dates:
- October 17, 2031✓
- October 17, 2031
More about Ionsys (fentanyl)
- Ionsys consumer information
- Check interactions
- Compare alternatives
- Latest FDA alerts (14)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: Opioids (narcotic analgesics)
- Breastfeeding
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.